Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Amplia Therapeutics ( (AU:ATX) ) just unveiled an announcement.
Amplia Therapeutics Limited announced a change in the director’s interest for Dr. Warwick Tong, as reflected in the attached Appendix 3Y. This update involves changes in the allotment and expiry of shares and options held by Dr. Tong. Such changes in director’s interests can impact stakeholder perceptions and reflect internal strategic adjustments within the company.
The most recent analyst rating on (AU:ATX) stock is a Buy with a A$0.42 price target. To see the full list of analyst forecasts on Amplia Therapeutics stock, see the AU:ATX Stock Forecast page.
More about Amplia Therapeutics
Amplia Therapeutics Limited is an Australian pharmaceutical company focused on developing Focal Adhesion Kinase (FAK) inhibitors for treating cancer and fibrosis. The company has a particular emphasis on fibrotic cancers, such as pancreatic cancer, and is also involved in addressing chronic diseases like idiopathic pulmonary fibrosis (IPF).
YTD Price Performance: 74.16%
Average Trading Volume: 7,216,964
Technical Sentiment Signal: Hold
Current Market Cap: A$79.53M
Find detailed analytics on ATX stock on TipRanks’ Stock Analysis page.